产品信息
| 产品号 | 商品名 | 活性成分 | 剂型/给药途径 | 规格/剂量 | 参比药物(RLD) | 生物等效参考标准(RS) | 治疗等效代码 | 该申请号批准日期 | 该产品号批准日期 | 市场状态 |
|---|---|---|---|---|---|---|---|---|---|---|
| 001 | BRIXADI | BUPRENORPHINE | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 8MG/0.16ML (50MG/ML) | Yes | No | None | 2023/05/23 | 2023/05/23 | Prescription |
| 002 | BRIXADI | BUPRENORPHINE | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 16MG/0.32ML (50MG/ML) | Yes | No | None | 2023/05/23 | Prescription | |
| 003 | BRIXADI | BUPRENORPHINE | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 24MG/0.48ML (50MG/ML) | Yes | No | None | 2023/05/23 | Prescription | |
| 004 | BRIXADI | BUPRENORPHINE | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 32MG/0.64ML (50MG/ML) | Yes | No | None | 2023/05/23 | Prescription | |
| 005 | BRIXADI | BUPRENORPHINE | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 64MG/0.18ML (356MG/ML) | Yes | No | None | 2023/05/23 | Prescription | |
| 006 | BRIXADI | BUPRENORPHINE | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 96MG/0.27ML (356MG/ML) | Yes | No | None | 2023/05/23 | Prescription | |
| 007 | BRIXADI | BUPRENORPHINE | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 128MG/0.36ML (356MG/ML) | Yes | Yes | None | 2023/05/23 | Prescription |
